Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Lymphoid 1Dermatologic 1

Conditions

Sezary Syndrome 1Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 1Mycosis Fungoides 1Lymphoma, T-Cell, Cutaneous 1Lymphoma, Large-Cell, Anaplastic 1Lymphoma 1Immunoblastic Lymphadenopathy 1

Interventions

Peripheral Blood Stem Cell Transplantation 38fludarabine phosphate 34Cyclophosphamide 29Mycophenolic Acid 25Cyclosporine 23Whole-Body Irradiation 22Tacrolimus 21Busulfan 18Antilymphocyte Serum 17Methotrexate 15Radiotherapy 14Flow Cytometry 13Filgrastim 13Etoposide 13Methylprednisolone 10Bortezomib 10Vorinostat 9Melphalan 9Therapeutics 8Psychiatric Rehabilitation 8Polymerase Chain Reaction 8Lenalidomide 8Rituximab 7Gemcitabine 7Cord Blood Stem Cell Transplantation 6Bexarotene 6tanespimycin 5fludarabine 5aldesleukin 5Transplantation 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Sezary Syndrome × visilizumab × Dermatologic × Clear all
NCT00006009 2013-05-15

Monoclonal Antibody Therapy in Treating Patients With Advanced or Recurrent Lymphoma

National Cancer Institute (NCI)

Phase 1 Completed
DermatologicLymphoidOther hematologic neoplasm

Immunoblastic Lymphadenopathy, Lymphoma, Mycosis Fungoides, Sezary Syndrome, Lymphoma, T-Cell, Cutaneous, Lymphoma, Large-Cell, Anaplastic, Precursor T-Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡